EUVIMEDEUVIMED entdecken
Crossref

Net survival in colon and rectal cancer by stage according to neoadjuvant treatment. A French population-based study

Valérie Jooste, Pascale Grosclaude, Gautier Defossez, Laetitia Daubisse, Anne-Sophie Woronoff, Véronique Bouvier, Emmanuel Chirpaz, Brigitte Tretarre, Bénédicte Lapotre, Sandrine Plouvier, Guy Launoy, Mélanie Bonneault und 3 weitere

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2023.10.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Valérie Jooste und 14 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Cancer Registry of Burgundy, Dijon, France; Dijon University Hospital, Dijon, France; INSERM UMR 1231 EPICAD, Dijon, France; University of …. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Neoplasm Staging, Rectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Real-life estimations of survival by stage in colorectal cancer are scanty. We estimated population-based net survival by pathological stage and location, and for rectal cancer by patterns of evolution according to clinical and pathological stage with regard to neoadjuvant therapy. METHOD: Age-standardized net survival was estimated on 19,630 colorectal cancers diagnosed between 2009 and 2015. RESULTS: Five-year net survival was 64 % for colon and 62 % for rectal cancer. The highest absolute difference between colon and rectum was 12 % for stage II women aged 75 (91% vs. 79 %). Among patients with clinical stage III rectal cancer, 67 % no longer had pathological node involvement after neoadjuvant treatment. Survival was similar in clinical stage I, II or III and pathological stage III after neoadjuvant treatment and in pathological stage III without neoadjuvant treatment (between 67 % and 72 %). It ranged between 80 and 82 % in pathological stage II, without neoadjuvant treatment or with clinical stage I, II or III before neoadjuvant treatment. Survival ranged between 93 % and 95 % in pathological stage I, treated with surgery only or with clinical stage II or III before neoadjuvant treatment. CONCLUSION: Prognosis is associated with stage determined on surgical specimens rather than stage at the initial workup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyNeoplasm StagingRectal NeoplasmsHumansFemaleFranceAgedMaleMiddle AgedAged, 80 and overColonic NeoplasmsPrognosisAdultSurvival Analysis

Stichwörter der Autor:innen

Clinical stageColorectal cancerPathological stagePopulation-basedSurvival

Autor:innen und Institutionen

  • Digestive Cancer Registry of Burgundy, Dijon, France; Dijon University Hospital, Dijon, France; INSERM UMR 1231 EPICAD, Dijon, France; University of Burgundy, Dijon, France; FRANCIM Network, Toulouse F-31073, France.
  • FRANCIM Network, Toulouse F-31073, France; Tarn Cancer Registry, Claudius Regaud Institute, IUCT-O, Toulouse, France; CERPOP INSERM U1295, Toulouse III University, F-31000, France.
  • FRANCIM Network, Toulouse F-31073, France; Registre général des cancers de Poitou-Charentes, Poitiers University Hospital, France; INSERM Centre d'Investigation Clinique CIC1402, Poitiers, France.
  • FRANCIM Network, Toulouse F-31073, France; Doubs Cancer Registry, Besançon University Hospital, Besançon, France; Research Unit EA3181, Franche-Comté University, Besançon, France.
  • FRANCIM Network, Toulouse F-31073, France; ANTICIPE U1086 INSERM-UCN, Centre François Baclesse, Normandie UNICAEN university, Caen, France; Calvados Digestive Cancer Registry, University Hospital Centre, Caen, France.
  • FRANCIM Network, Toulouse F-31073, France; INSERM, CIC 1410, Reunion University Hospital, Saint-Pierre, France; Cancer Registry of Reunion Island, Reunion University Hospital, Saint-Denis, France.

Zitieren

APA

Jooste, V., Grosclaude, P., Defossez, G., Daubisse, L., Woronoff, A. S., Bouvier, V., Chirpaz, E., Tretarre, B., Lapotre, B., Plouvier, S., Launoy, G., Bonneault, M., Molinié, F., Bouvier, A. M., & FRANCIM Network (2024). Net survival in colon and rectal cancer by stage according to neoadjuvant treatment. A French population-based study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.10.012

Vancouver

Jooste V, Grosclaude P, Defossez G, Daubisse L, Woronoff AS, Bouvier V, et al. Net survival in colon and rectal cancer by stage according to neoadjuvant treatment. A French population-based study. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.10.012

BibTeX
@article{Jooste2024,
  author = {Jooste, Valérie and Grosclaude, Pascale and Defossez, Gautier and Daubisse, Laetitia and Woronoff, Anne-Sophie and Bouvier, Véronique and Chirpaz, Emmanuel and Tretarre, Brigitte and Lapotre, Bénédicte and Plouvier, Sandrine and Launoy, Guy and Bonneault, Mélanie and Molinié, Florence and Bouvier, Anne-Marie and FRANCIM Network, FRANCIM Network},
  title = {Net survival in colon and rectal cancer by stage according to neoadjuvant treatment. A French population-based study},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2023.10.012}
}
Kostenlos starten →